The content on this site is intended for healthcare professionals only
Prof Dennis Slamon presents data from the MONALEESA-3 trial during a press conference at the 2019 ESMO congress.
This was a trial looking at treatment with the CDK4/6 inhibitor ribociclib plus fulvestrant in postmenopausal patients with HR HER2- advanced breast cancer.
Watch Prof Slamon's interview with ecancer here.
Read more on this study here.
ASCO 2026: Breast cancer overview
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
